Steven Holtzman is a non-voting member of the Evrys Bio Board of Directors. Most recently he has was the president and CEO of Decibel Therapeutics. Prior to Decibel, he served as executive VP, corporate development at Biogen, Inc., where he led eight new drug approvals. Previously, Steve was the founder, chief executive officer, and board chair of Infinity Pharmaceuticals, Inc. He was also an early leader and the chief business officer of Millennium Pharmaceuticals (now Takeda Oncology) and was a founder, board member, and executive VP of DNX Corporation. He was appointed by President Clinton to the National Bioethics Advisory Commission and also served as a member and vice-chair of the board of the Hastings Center for the Life Sciences.